Form 4: IGM Biosciences Director Exits Board Post-Merger

IGM Biosciences director Michael Lee reported the sale of 12,712 common shares following the company's merger with Concentra Biosciences, receiving $1.247 cash and a CVR per share.

Summary

• Michael Lee, a director and 10% owner of IGM Biosciences, Inc. (IGMS), reported the disposition of 12,712 shares of common stock.
• The transaction occurred on August 14, 2025, as a result of a merger agreement dated July 1, 2025, among IGM Biosciences, Concentra Biosciences, LLC, and Concentra Merger Sub V, Inc.
• A tender offer by Concentra Merger Sub V, Inc. to acquire all outstanding shares of IGM Biosciences Common Stock and Non-Voting Common Stock concluded on August 13, 2025, at 11:59 p.m. Eastern Time.
• Shareholders received $1.247 in cash per share, plus one Contingent Value Right (CVR) per share, subject to applicable tax withholding and without interest.
• Following the transaction, Michael Lee's direct beneficial ownership of IGM Biosciences common stock is 0 shares.
• Mr. Lee held these securities as a nominee for Redmile Group, LLC, and disclaims beneficial ownership, having assigned all economic, pecuniary, and voting rights to Redmile.
• Mr. Lee resigned from the board of directors immediately prior to the merger's effective date.

Sentiment

Score: 6

Explanation: The filing reports the successful completion of a merger, providing liquidity to shareholders and potential future value through Contingent Value Rights (CVRs). While it marks the end of the company's independent public trading, the transaction itself is a definitive event that delivers value to shareholders.

Positives

• The merger successfully completed, providing liquidity to IGM Biosciences shareholders.
• Shareholders received a cash payment of $1.247 per share.
• Shareholders also received a Contingent Value Right (CVR) per share, offering potential future value tied to specific terms and conditions.

Negatives

• The reporting person, a director and 10% owner, no longer holds shares in the company following the merger, indicating the cessation of their direct equity interest.

Risks

• The ultimate value of the Contingent Value Right (CVR) is subject to future terms and conditions, introducing uncertainty regarding its final realization.

Future Outlook

The future value of the Contingent Value Right (CVR) is dependent on specific terms and conditions outlined in a separate Contingent Value Rights Agreement, which will determine any additional payments to former shareholders.

Management Comments

• Mr. Lee, a managing director of Redmile, resigned as a member of the board of directors of the Issuer immediately prior to the effective date and time of the merger between Issuer and Merger Sub.
• Mr. Lee disclaimed beneficial ownership of the reported securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee was the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
• Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Industry Context

The acquisition of IGM Biosciences by Concentra Biosciences, including a Contingent Value Right (CVR), aligns with common trends in the biotechnology and pharmaceutical sectors where companies with promising pipelines are acquired, often with a portion of the consideration tied to future clinical or regulatory milestones. This structure allows the acquirer to mitigate risk while providing potential upside to the acquired company's shareholders.

Comparison to Industry Standards

• The inclusion of a Contingent Value Right (CVR) in the merger consideration is a common practice in biotech acquisitions, particularly when the acquired company's value is heavily tied to the success of specific drug candidates or clinical milestones. This mechanism has been observed in deals such as the acquisition of Acceleron Pharma by Merck (where CVRs were tied to sotatercept approval) or the acquisition of MyoKardia by Bristol Myers Squibb (where CVRs were tied to mavacamten approval).
• The $1.247 cash component, combined with the CVR, represents the final valuation for IGM Biosciences shareholders in this specific transaction, consistent with how such deals are structured in the industry.

Management Changes

Related Party Transactions

• Michael Lee held the reported securities as a nominee on behalf of, and for the sole benefit of, Redmile Group, LLC, assigning all economic, pecuniary, and voting rights to Redmile.
• Jeremy Green, as the principal of Redmile, may also be deemed beneficially to own the securities, with Redmile and Mr. Green disclaiming beneficial ownership except to the extent of their pecuniary interest.

Stakeholder Impact

• Shareholders: Received cash and Contingent Value Rights (CVRs) for their shares, indicating a liquidity event and potential future upside.
• Management: Michael Lee, a director, resigned from the board.

Next Steps

• Future value realization from Contingent Value Rights (CVRs) based on their specific terms and conditions.

Key Dates

Keywords

IGM Biosciences, IGMS, Form 4, insider transaction, beneficial ownership, merger, tender offer, Redmile Group, Contingent Value Right, CVR, corporate acquisition